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ABSTRACT
Determining Protein Biomarkers for Chemotherapeutic 
Drug Resistance in Breast Cancer
by
Shauna Durocher
Dr. Bryan Spangelo, Examination Committee Chair 
Professor o f Biochemistry 
University o f Nevada, Las Vegas
Although there have been many research advances in the treatment and prevention o f 
cancer, it remains a leading cause o f death each year throughout the world. A major 
obstacle in the treatment o f cancer is encountered when the cancer develops resistance to 
chemotherapeutic agents. To better understand resistance and identify biomarkers we 
propose to develop resistance in breast adenocarcinoma cancer cell lines, M DA-M B-231 
and MCF-7, using common chemotherapeutic agents, doxorubicin and cisplatin. 
Microarray analysis will be preformed to identify over expression o f proteins in these 
resistant lines. We hypothesize that genes which are over-expressed in a resistant cancer 
cell line may be responsible for the observed chemoresistance. To test this hypothesis, 
chemical inhibitors will be used to suppress protein expression in resistant and wild type 
cell lines, and then perform proliferation and viability assays to observe changes in 
protein synthesis from over expressed genes.
Our preliminary results indicated 10 genes which were highly over-expressed in the
resistant cancer cell line SD231RD2 in comparison to the M DA-M B-231 wild type
iii
cell line. We chose to focus on two genes, reported in the literature to be commonly 
expressed in response to stress, resulting in increased production o f cyclooxygenase-2 
(COX-2) and metalloproteinase-3 (MMP-3). Inhibition o f COX-2 protein with 
indomethacin using clonogenic survivals reversed chemoresistance in resistant cells.
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CHAPTER 1
INTRODUCTION
1.1 Purpose o f the Study 
The development o f the first documented anticancer agent occurred in 1943 when Dr. 
Louis Goodman and Dr. Alfred Gilhnan reported that the alkylating agent nitrogen 
mustard could induce regression o f lymph node enlargement in malignant lymphoma (1). 
Our ongoing battle to discover new efficient treatments for cancer continues today, with 
cancer being responsible for one in every four deaths in America. The American Cancer 
Society estimates that there will be over 1.4 million new cases o f cancer diagnosed in 
2008 and half o f those are expected to die from the disease. Approximately 185,000 o f 
these estimated cases will be diagnosed with breast cancer (2).
Breast cancer is positively correlated with age, an onset o f menses that occurs early in 
life and ends late in life, never having children or having the first child after the age of 
thirty, and inherited genetic mutations in BRCAl and BRCA2. Treatments for breast 
cancer include surgery (partial or full mastectomy), chemotherapy, radiation therapy and 
hormone therapy (2). Although treatment options are available to patients that have been 
diagnosed with cancer, in recent years there have been no advances in gene therapy for 
patients. Because anticancer agents have different efficacies among patients due to 
individual differences in gene expression profiles, predicting productive outcomes in
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patients remains problematic (3). Another major drawback o f using chemotherapy is that 
cancers may develop resistance to therapy due to changes in gene expression. Also, 
patients undergoing treatment with anticancer agents may be initially resistant to a 
specific treatment or may become resistant. If this occurs, the patient’s cancer may 
progress which requires utilization o f alternate therapies. If  multi drug resistance occurs 
the typical outcome for the patient is death.
1.2 Significance o f Study 
The development o f an in vitro resistant cancer cell line to a specific 
chemotherapeutic agent can provide detailed gene expression patterns that will 
demonstrate potential protein biomarkers that may be responsible for cancer resistance. 
This experimental outcome could potentially improve selection o f effective therapy 
strategies for individual cancer patients. Successful therapy would follow after 
examination o f gene expression profiles o f tumors to specify which genes are over or 
under expressed. The physician would then treat the patient with the anticancer agent that 
would best combat that type o f cancer based on factors such as the gene expressed that 
would render a patient sensitive or resistant to specific anticancer agents. The results from 
a gene expression profile could also allow use o f blocking agents to inhibit genes that are 
responsible for chemoresistance.
1.3 Research Tasks
To determine gene expression profiles and possible biomarkers for treatment o f 
chemoresistant breast cancers, data will be collected from the following tasks performed:
1. Preparation o f a resistant breast cancer cell line;
2. Determine by microarray analysis which genes are overexpressed in the 
resistant cancer cell line compared to wild type;
3. Identify the pathway or mechanism involving the overexpressed genes;
4. Determine if  an inhibitor o f protein expression will restore sensitivity to 
the anticancer agent in the resistant line.
CHAPTER 2
REVIEW OF RELATED LITERATURE
2.1 Gene Expression in Resistant Cancer 
Microarray analysis has been performed on multiple cancer cell lines and tumors 
treated with varying anticancer agents in vitro to determine which genes are responsible 
for resistance or sensitivity to specific chemotherapeutic agents. The results allow 
researchers to determine if  drugs with similar modes o f action will regulate the same 
clusters o f genes involved in chemoresistance (4). Cancer chemotherapy is limited by the 
emergence o f chemotherapeutic resistant tumor cells. For example, the gene identified as 
M DR is a multidrug resistant gene that exhibits cross resistance to a variety o f anticancer 
agents when P-glycoprotein (P-gp) is over expressed. This protein is responsible for 
increasing the removal o f the anticancer agent from the cell, thereby reducing the efficacy 
o f the drug (5). Researchers have found a variety o f genes specific for each cancer type 
that may cause resistance to specific anticancer agents, in-vitro. Once resistance develops 
in a cell line the possibility o f multidrug resistance also increases, which limits treatment 
success.
2.2 Wild Type vs. Resistant Cancer Cell lines 
Two human breast adenocarcinoma cell lines, MDA-MB-231 and MCF-7, are the 
main targets o f interest and are used as model systems. M DA-M B-231 was established 
from a biopsy o f a tumor from the breast o f a 51 year old Caucasian female, and MCF-7 
was established from a biopsy o f a tumor from the breast o f a 69 year old Caucasian 
female (www.atcc.org). These cell lines differ in one main aspect: the MCF-7 cancer cell 
line is positive for an estrogen receptor (ER^), whereas the M DA-M B-231 does not 
express an estrogen receptor (ER ). These cell lines differ in their responses to 
chemotherapy, which allows resistance to develop in one cell line but not in another due 
to differing gene expressions (6). It is also predicted that tumors which are ER' have a 
poorer prognosis following chemotherapy compared to patients with ER^ tumors who 
have longer, disease free survival rates (7).
Our goal is to develop M DA-M B-231 and MCF-7 cell lines resistant to anticancer 
agents without manipulating the presence o f specific genes. This approach differs from 
the typical method in which cells lines have specific genes removed, resulting in 
resistance to specific anticancer agents. For example, AdrR MCF-7 is resistant to 
adriamycin up to 10 pM, which produces resistance to benzo(a)pyrene (8). Instead of 
purchasing a cell line that is resistant to a specific anticancer agent, we chose to convert 
the wild type cell lines MDA-MB-231 and MCF-7 to resistant lines by continual 
exposure to either doxorubicin or cisplatin. By producing these cell lines in this manner, 
we can determine which genes are responsible for the development o f  resistance to 
anticancer agents. This approach allows systematic adaptation for resistance within the 
biological system, rather than artificial manipulation achieved by intentional genetic
5
change, to determine the factors which are responsible for resistance to 
chemotherapeutics. The process o f selecting resistant clones is described in Figure 1.
Seed cdl:, and iocnbate at SM CO; ^  37*C for 
appro:. Ihree deyr
When cell deiuity reached 40% confloeacy cdt* 
were treated with mdicated dreg and 
concentcaËon
When cdl denrity reached 83% cooBueocy, ceDe 
are pa«ed (1 mL) without drug
Alter 24h incubation, drug* are added to the 
cdl* agaia
IF cdl* grown to 70% cceBueocy then etepa 3 
and4 ate repeated
Approaimately at one mouth cdl morphology 
change* and celli «top proliferating
frerh media and drugget* replnced twice a wedc
i
Cells will continue to die until they reach 1-5% 
confluency, thi: »tq> take* approximately three
months
i
After approximatdy *ùr month* to one year the 
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pl#es,m  the presence of drug
i
Thi* cobay will continue toprohferate and move 
From 48 well plate into aT23 Bask, thi* stqr
takes approximately two weeks, cells are always 
in drug
Figure 1. Protocol for the development o f resistant cancer cell lines. The incubation 
environment is maintained at 37°C, 95% relative humidity and 5% CO;.
2.3 Cisplatin and Doxorubicin 
Cisplatin and doxorubicin are common anticancer agents used in chemotherapy 
regimens. However, cancer can become resistant to these anticancer agents. The
structures o f these compounds are illustrated in Figure 2. Overcoming resistance by 
finding novel biomarkers will aid with early detection to avoid development o f resistant 
tumors or allow for quicker detection o f resistance providing an earlier opportunity to 
alter the chemotherapy strategy. To better understand the mechanism of action requires 
genetic profiling within resistant tumors to determine the cause o f resistance.
B
n ,r n Cl.. NH3 
C l ^  ^ N H 3
Figure 2. Structures o f chemotherapeutic agents. Doxorubicin (DOX) chemical structure 
is shown in A. (Source:http://www.ffeepatentsonline.com/6653455-Q-displav.ipgT while 
cisplatin (CDDP) chemical structure is shown in B.
(Source:http://upload. wikimedia.org/).
The lethality o f cisplatin is attributable to irreversible adduct formation to the DNA 
backbone through a reaction with the seventh nitrogen (N7) of adjacent guanines 
(Figure 3). Cisplatin can enter the cell by passive diffusion or active uptake. Passive 
diffusion can occur because the chloride ion concentration is much lower inside the cell 
then on the outside. Once in the cell, cisplatin undergoes hydrolysis and exchanges its 
chloride atoms for hydroxyl (OH) groups. The OH groups will then be able to make 
interstrand and intrastrand crosslinks to the seventh nitrogen (N7) o f adjacent guanines 
(Figure 3) to form a bulky lesion in the DNA backbone which ultimately results in the 
recruitment o f DNA repair mechanisms. If  the lesion cannot be repaired, the cell
undergoes programmed cell death via the apoptotic pathway (9-10). Some mechanisms 
involved in the cellular resistance o f cisplatin include reduced drug uptake, increased 
drug efflux, and increased DNA repair (11). For example, in the case o f reduced drug 
uptake 90% of cisplatin when given intravenously will bind to plasma proteins, thus the 
agent never reaches target cells, leading to inactivation o f many cisplatin molecules (10). 
If  products o f gene expressions in these pathways could be indentified it is possible the 
genes could be targets for monitoring resistance.
Figure 3. Cisplatin interaction to the N7 of guanine or adenine on DNA backbone. 
Percentages represent how many adducts are formed with the specific crosslink stated. 
(Source:www.icu.edu.au/.../research/cisplatinweb.htmf
The effects o f doxorubicin are complex, but one nuclear action is mediated by 
indirect inhibition o f topoisomerase II activity (Figure 4). The drug interferes with DNA 
winding by intercalation between the double helix which interferes with the ability o f 
topoisomerase II to unwind DNA for successful transcription (Figure 5). It has been 
found that a decreased level o f topoisomerase II hinders the efficacy o f doxorubicin (12), 
since there is lowered target that is available for doxorubicin. Additional data suggests 
that doxorubicin has the ability to induce DNA strand breaks which causes cell death 
through free radical mediated apoptosis (13).
/ , - .
*!
 ^ ^ : CYP3*ÿ' \  capi^^
r - /^Wotorwlrw! 1'NAU.:n#v*. -.  /
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Figure 4. Mechanism and pathways affected when doxorubicin enters the cancerous cell. 
ISource:http://www.pharmgkb.org/do/serve?obiId=PA155618789&obiCls=Pathwav)
Figure 5. Doxorubicin intercalation with DNA backbone. It is proposed that intercalation 
with doxorubicin will not allow for transcription therefore signalling programmed death 
in tumor cells. (Source:http://www.rsc.org/ei/CS/2007/b606Q46n/b606046n-fl3.gif)
2.4 Genes o f Interest
From the microarray data two proteins o f interest were discovered. The first gene o f 
interest is cyclooxygenase-2 (COX-2 also known as PGH synthase), a glycoprotein 
regulated at both transcription and post transcriptional levels by proinflammatory agents, 
cytokines, growth factors, oncogenes and tumor promoters. It is known that COX-2 is 
expressed in the early stages o f carcinogenesis (14). As shown in Figure 6, COX-2 is 
involved in the conversion o f arachidonic acid into prostaglandins. This conversion is 
crucial since prostaglandin E; (PGE;), one o f the end products o f the arachidonic acid 
pathway, is also responsible for mitogenesis and tumor growth (15). COX-2 expression 
activates the phosphatidyl inositol 3-kinase/AKT signalling pathway, a biochemical 
pathway which signals for cell survival (16). COX-2 and PGE; play important roles in
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regulating tumor invasion, angiogenesis and apoptotic resistance. In addition, COX-2 and 
PGE; each promote malignant growth (17).
The other gene o f interest is matrix metalloproteinase-3 (MMP-3 or stromelysin). This 
protein is synthesized and secreted from connective tissue cells and degrades several 
extracellular matrix molecules (18). MMP-3 is known to promote tumor formation and 
cell proliferation by release o f growth factors, and has been shown to impede tum or 
relevant processes such as apoptosis (19).
coon
Arachidonic acid
COOM
- inldbil*)
HO OH
PGlj (unstable)
pfaataqrdin
«ynthaib^ ,^
COOH 0-1
HO
Prostacyclin»
HO OH
t
COOH
HO
y ^ . X ' X X ' r
HO OH
PGH;
n o
I/A I
com
OH
thro nb X 
kvn h
OH
Thrombaxancg
HO^O'
OH
T * A j j ( o n « t a W e )
1
COOH
!
O H
com(
X s .: /— s X  HQ
OH
PGR:.
Prostaglandin» ,
TitB*
COOH
n
0 OH
pcm.
Figure 6. The cyclic pathway o f arachidonic acid metabolism (20). The pathway branches 
demonstrate synthesis o f the prostaglandin o f interest PGE;. PGH synthase is also known 
as COX-2.
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2.5 Hypothesis
Although advances are being made in treatments provided for patients with cancer, 
many patients still have a poor prognosis due to chemoresistance. It is important to try to 
determine what causes resistance in human cancer cell lines and tumors. I f  we could 
determine which proteins are responsible for resistance in cancer cells we could provide a 
better treatment option for the patient. Our hypothesis is that a small subset o f proteins 
provide protection against a wide variety o f anticancer agents, knowing these proteins 
will allow us to determine better chemotherapeutic treatments for patients. To test this 
hypothesis two established breast cancer cell lines MCF-7 and M DA-M B-231 will be 
made resistant to two common chemotherapeutic agents cisplatin and doxorubicin. The 
resistance to these agents will be confirmed by proliferation and viability assays. Once 
established, these resistant cell lines will be analyzed by microarray analysis to reveal 
over and under expressed gene expressions. Gene expression o f  the resistant cells will be 
compared to parental cell lines. Those gene messages showing the largest increase in 
expression will be investigated further. The importance o f elevated messages will be 
investigated by inhibiting the function (chemical inhibitor) o f the protein.
12
CHAPTER 3
MATERIALS AND METHODS 
The samples and drag preparations that required the use o f water were completed 
using ultrapure water. All chemicals and reagents are o f highest quality grade. All cancer 
cell lines were maintained at 95% humidity, 5% CO 2 and 37 °C unless otherwise stated.
3.1 Cell Culture
Human breast cancer cell lines M DA-M B-231 and MCF-7 were obtained from the 
American Type Culture Collection (Manassas, VA, USA). M DA-M B-231 and MCF-7 
were both cultured in MEM medium (containing Earle’s Salts and L-glutamine, 
Invitrogen, USA) supplemented with 10% fetal bovine serum (Invitrogen, USA), 25mM 
HEPES pH 7.4 (Sigma-Aldrich, USA) and 1% penicillin-streptomycin (Invitrogen,
USA). Resistant lines were also cultured in MEM medium with either 0.01 pM  
doxorubicin (Sigma-Aldrich, USA) or cisplatin (Sigma-Aldrich, USA). Cells were 
incubated at 5% CO2 and 37 °C in 95% humidity. Cell harvests were obtained by washing 
cells three times in phosphate buffered saline (PBS at pH7.2) which did not contain CaCli 
or MgCL (Invitrogen, USA) and chemically detaching adherent cells from the surface o f 
the flask using trypsin-EDTA (0.25% Trypsin with 53mM EDTA) in HBSS without 
calcium and magnesium (ATCC, Manassas, VA) for ten min. Fresh medium was added
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to inactivate trypsin. Cells counts were performed using a Z1 Beckman Coulter® Particle 
Counter (Fullerton, CA).
3.2 Z1 Beckman Coulter® Particle Counter 
To determine cell numbers in cell suspensions (0.1 mL) o f attached cells was added to 
a coulter counter cup containing 9.9 mL o f isotonic diluent azide-free (Isoton) solution 
(Val-Tech Diagnostics Inc., Pittsburgh, PA). The solution was stirred and placed in the 
Z1 Beckman Coulter® Particle Counter (Fullerton, CA). Two or three measurements 
were averaged and used to calculate the number o f cells per mL o f solution.
3.3 Preparation o f Cisplatin, Doxorubicin and Indomethacin 
A 50 mM  stock o f cisplatin was prepared by dissolving 0.150 grams o f  300.05 g/mol 
cisplatin (CDDP; Sigma-Aldrich, USA) in 10 mL o f dimethyl sulfoxide (DMSO; Sigma- 
Aldrich, USA). The solution was filtered using a syringe (Becton Dickinson, USA) under 
sterile conditions with a 0.2 pM  nylon membrane syringe filter (PALL, Aim Arbor, Ml). 
Serial dilutions were made using 500 pL o f the 50 mM stock diluted in 4.5 mL o f sterile 
filtered DMSO.
A 5 mM stock o f doxorubicin was prepared by dissolving 0.029 grams o f  579.98 
g/mol doxorubicin (DOX; Sigma-Aldrich, USA) in 10 mL o f water. The solution was 
filtered using a syringe under sterile conditions with a 0.2 pM  polyethersulfone 
membrane syringe filter (VWR International, USA). Serial dilutions were m ade using 
500 pL o f the 50 mM stock diluted in 4.5 mL o f sterile filtered water.
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A 500 mM stock of indomethacin was prepared by dissolving 1.789 grams o f 357.79 
g/mol indomethacin (Sigma-Aldrich, USA) in 10 mL o f DMSO. The solution was filtered 
using the aforementioned procedure. Serial dilutions were made using 500 pL o f the 500 
mM stock diluted in 4.5 mL of sterile filtered DMSO.
3.4 Mitochondrial Dehydrogenase Assay 
Cellular mitochondrial dehydrogenase activity was determined using the AlamarBlue 
assay (BioSource, Camarillo, CA). Varying amounts o f cells were seeded in a 96-well 
plate in 0.1 mL aliquots and allowed to adhere for an incubation time o f 24 h Triplicate 
wells were exposed to varying concentrations o f either doxorubicin or cisplatin prepared 
in cell culture medium. The first row o f the plate did not contain cells and was used as a 
blank measurement. Following exposure to test substances, plates were incubated for 24 
and 48 hour time periods. After incubation, 0.1 mL fi*esh cell culture media, and 0.01 mL 
AlamarBlue was added to each well. The plates were then incubated for 4 h. Absorbance 
of each well was measured using a GENios fluorescence plate reader (Tecan Systems Inc. 
San Jose, CA) at excitation and emission wavelengths o f 530 nm and 590 nm, 
respectively. Percent viability was reported as a percent o f controls (n=3).
3.5 Colony Formation Assay (Clonogenic Survival)
Tissue culture flasks (25 cm^) were seeded with 50 x 10  ^ (MDA-MB-231) cells, 150 x 
10  ^ (SD231RD2) cells or 150 x 10  ^ (MCF-7) cells and incubated for 72 h. After this 
incubation period, the cells were treated with varying concentrations o f doxorubicin or 
cisplatin and incubated for 1 h  or 24 h (control cells were treated with the drug vehicle).
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Cells were harvested, counted, and dilutions were prepared such that 150 cells (MDA- 
M B-231), 300 cells (SD231RD2) or 200 cells (MCF-7) were sub-cultured in triplicate in 
60 mm X 15 mm cell culture dishes (Coming Inc., USA). Dishes were incubated for 10 
days, and stained with crystal violet (0.5% weight/volume crystal violet in 95% ethanol, 
Sigma-Aldrich, USA), and colonies (n > 50 cells) counted. Percent survival compared to 
control cells was measured (n = 3).
Indomethacin inhibition o f COX-2 survival: To maintain consistent confluencies, 
tissue culture flasks (25 cm^) were seeded with 50 x 10  ^ (M DA-M B-231) cells and 
incubated for 72 h, while flaks containing SD231RD2 were seeded with 150 x 10  ^ cells 
and incubated for 48 h. After this incubation period cells were treated with varying 
concentrations o f doxombicin and 50 pM  indomethacin then incubated for 24 h (control 
cells were treated with drug vehicle). Other controls included triplicate plates treated only 
with the lethal dose 50% ( L D 5 0 )  of doxorubicin, and triplicate plates treated only with 
indomethacin. Cells were harvested, counted, and dilutions were prepared such that 150 
cells (MDA-MB-231), 300 cells (SD231RD2) were plated in triplicate in 60 mm x 15 
mm cell culture dishes. Dishes were incubated for 10 days, stained with crystal violet, and 
colonies (n > 50 cells) counted. Percent survival compared to control cells was measured 
(n = 3).
3.6 Six Day Viability Assay 
Tissue culture flasks (25 cm^) were seeded in triplicate for each dmg time with 50 x 
10  ^ (M DA-M B-231) cells and 150 x 10  ^ (SD231RD2). Cells were maintained in MEM 
and incubated for 24 h (day 0). After this incubation period cells were treated, referred as
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day one, with varying concentrations o f doxorubicin (control cells received water). Flasks 
were then incubated for two more days. On day three, each o f the flasks were harvested 
separately and re-seeded in one-eighth o f the volume (625 pL) into a new flask 
containing 4275 pL o f MEM and 100 pL o f doxorubicin drug (specific concentration for 
each drug point). Flasks were then incubated for three more days. On day six, cells from 
each flask were harvested separately and the cell density was determined in cells/mL by 
conducting cell counts.
3.7 RNA Extractions 
Cells were passed at the same time each day for a total o f three passages and 
maintained at 50-60% confluency. Media was removed from the triplicate flasks 
containing M DA-M B-231 or SD231RD2 and rinsed three times with 5 mL o f PBS. Cells 
were then harvested and transferred to a 15 mL conical vial. Total RNA extractions were 
then performed according to protocol using QIAGEN RNeasy MINI Kit purification 
system (QIAGEN, USA). The resulting solution was separated into aliquots for the 
purpose o f microarray analysis (Windber), Polymerase Chain Reactions (PCR), 
quantitation, and verification o f purity. The aliquots are immediately stored at -70°C until 
further use.
3.8 Instructions for RNA Quantification and Purification on NanoDrop 
To ensure the integrity o f the RNA, all samples remained on ice and were handled 
using RNase free materials. A 1:9 dilution o f sample to Tris buffer was prepared for the 
purpose o f verifying sample purity The NanoDrop (ND-1000 spectrophotometer. Thermo
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Scientific, USA) instrument was set to zero using RNase free water prior to measuring 
the absorbance o f the samples. A total o f 2 pL o f sample was loaded onto the sensor to 
measure the absorbance at 260 and 280 nm. The sensor was thoroughly cleaned using 
RNase free water between sample readings. Each sample was measured twice and the 
average measurement is used in data analysis. Concentration o f RNA was calculated by 
the NanoDrop software. To verify purity, the samples diluted in Tris buffer was measured 
and only samples with an A260/280 reading within 1.8-2.3 were used for microarray 
analysis.
3.9 Microarray Analysis 
Microarray Analysis was performed by Windber Research Institute (Windber, PA) 
using Affymetrix GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, Santa 
Clara, CA, USA) for this study. It is a single array with over 47,000 transcript probe sets 
representing over 38,500 well-substantiated human genes. W indber followed the 
Affymetrix GeneChip® Expression Analysis Technical Manual for all GeneChip array 
procedures. Briefly, one pg o f total RNA was used for reverse transcription to produce 
single strand cDNA followed by second strand synthesis to form double strand cDNA. 
After cDNA purification, biotin-labeled aRNA target wass produced by an in vitro 
transcription (IVT) reaction using the cDNA template. After aRNA purification, an 
aliquot o f the labeled aRNA is run on Agilent’s Bioanalyzer as a quality check and 
another aliquot is quantified using the NanoDrop UV/Vis spectrophotometer (NanoDrop). 
Only high quality RNA with a yield o f more than 10 pg was fragmented and hybridized 
to Affymetrix GeneChip arrays overnight (18 hours) in a temperature-controlled hyb-
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oven. After hybridization, GeneChip arrays were loaded onto a Fluidic Station 450 for 
washing and staining using the standard Affymetrix procedure. After the final wash, the 
GeneChip arrays were scanned using the Affymetrix GeneChip scanner 3000 G7.
Scanned images were analyzed using Affymetrix data analysis software (GDAS) to 
generate the raw data.
Data analysis included the use o f GDAS to generate many different files for each 
array. W indber imported the CEL file into GeneSpring microarray analysis software 
(Agilent). All six arrays were subjected to GCRMA processing then through log 
transformation and global normalization to generate normalized data. Probes were 
eliminated with raw signal intensity below 50 in four out o f six samples, resulting in
20,500 probe sets for further analysis. Because there were not enough replicates for each 
treatment, fold change was used (two fold as cut off) to identify differentially expressed 
genes for each comparison. The probe sets that were at least two fold different w ere 
further reduced by eliminating inconsistent points; i.e., if normalized signal value in  one 
o f the replicates is determined to be similar to the other group, it is considered a  potential 
false positive. For instance, (A l; 50; A2: 56) compare to (B l: 50; B2: 06). Average o f A 
and B are 53 and 23, respectively, ft is two-fold percent different between A and B 
(53/23 = 2.3). However, this specific data point is not included because the value o f  B l is 
50. The t-test was used to further reduce false positive probe sets when multiple replicates 
were available.
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3.10 Western Blot Analysis
M DA-M B-231 (250 x 10^) cells or SD231RD2 (400 x 10^) cells were seeded into a
75 cm^ flask and maintained with a total volume o f 10 mL o f MEM cell culture medium.
The resistant line (SD231RD2) was also supplemented with 200 pL o f 0.0005 mM stock
o f  doxorubicin, for a final concentration o f 0.01 pM  doxorubicin. After 3 days o f
incubation, the adherent cells were washed three times with 10 mL of PBS, discarding
each wash. Following the washing procedure, 5 mL of PBS was added to the flask and
cells were scraped and placed into a 15 mL conical tube. The cells were centrifuged at
room temperature for seven minutes at 1,500 rpm and supernatant discarded. To the
remaining cell pellet, 500 pL o f M-PER® cell lysis buffer (Pierce Rockford, IL) was
added in addition to 20 pL/mL phosphatase, 20 pL/mL protease and 10 pL/mL EDTA
(Pierce, Rockford, IL). The tube was then gently shaken for 5 minutes. The cells were
then centrifuged at 14,000 x g for 10 minutes at 4 °C to pellet cellular debris. The
resulting supernatant, containing all cellular proteins, was collected and stored at -20 °C
until further analysis
Protein concentrations were determined using the Bradford (Sigma-Aldrich, USA)
protein assay. Different masses o f protein standards (25, 50, 100,150, 200 pg) were used
to determine adequate amounts for detection o f proteins. Lysates were diluted by 25%
with sample loading buffer (PAGEgel, San Diego, CA) and 10% DDT reducer
(PAGEgel). The samples were placed in boiling water for 3 minutes, and then samples
were loaded into the wells o f a pre-casted 10% SDS-PAGE western blot gel in duplicate
(PAGEgel), the volume not to exceed 35 pL. In addition, purified protein samples were
loaded onto the gel and served as controls. A prestained protein ladder, SeeBlue plus
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(Invitrogen, USA) was used to insure transfer o f protein to membrane. For the COX-2 
protein standard (Oxford Biomedical Research, Oxford, MI) Ipg  per lane was used, and 
for the MMP-3 protein standard (USBiological, Swampscott, MA) 30 pL per lane was 
used. The gels were run in 1 x PAGEgel SDS running buffer (PAGEgel) according to the 
protocols o f PAGEgel 10x10cm SDS cassette gel running instructions, starting at 80 
mA/gel or 160 mA for two gels. Current was decreased every 15 minutes by 20 mA, 
ending at a current of 70 mA for an approximate run time o f 75-90 minutes. W hen the 
dye front reaches one inch from the bottom o f  the gel, it is transferred to a 0 . 2  pm 
nitrocellulose membrane (PAGEgel) using a constant current o f 280 mA for 60 min while 
in western transfer buffer (Tris-Glycine-SDS Run/Blot Stock Buffer, PAGEgel) and 20% 
v/v methanol (Sigma-Aldrich). Following the transfer, the membranes were placed in 
blocking solution with TBST (western wash, femto TBST lOX (G-Biosciences, St. Louis, 
MO), 0.1% Tween-20 (Sigma-Aldrich, USA) and 5% nonfat milk (Nestle Carnation) for 
I h, then washed three times with TBST until the solution was clear. The membrane was 
incubated in primary antibody (mouse anti-human) overnight at 4°C. The primary 
antibodies were diluted to a concentration o f  1:200 (COX-2), 1:100 (MMP-3), and 1:100 
(control, P-Actin) (Santa Cruz Biotechnology Inc., Santa Cruz, CA). All antibodies were 
diluted in TBST and 5% BSA. After incubation the primary antibody was removed and 
the membrane was washed with TBST three times for 5 min intervals. Then membranes 
are incubated in secondary antibody conjugated to a horseradish peroxidise (HRP) 
(1:2000) for 1 h  at room temperature (goat anti-mouse, Santa Cruz Biotechnology Inc.). 
After the Ih  incubation the secondary antibody was removed and the membrane was 
washed with TBST three times for 5 min intervals. Proteins were visualized on the
2 1
Typhoon multipurpose imager using Enhanced chemiluminescence ECL-plus® detection 
reagent (Amersham, Piscataway, NJ).
3.11 Semi-Quantitative RT-PCR
To confirm the data obtained through microarray analysis, semi-quantitative RT-PCR 
was performed. 100,000 (SD231RD2) cells were seeded in a T25 flask, maintained in 
MEM and 0.01 pM doxorubicin and 50,000 (MDA-MB-231) cells were seeded in a T-25 
flask, maintained in MEM without drug for 72 h. RNA was extracted and converted into 
cDNA using QuantiTec Reverse Transcriptase KIT (QIAGEN, Valencia, CA) and 
following the manufactures protocol.
PCR was carried out by using ProMega M aster Mix, (ProMega, Madison W l) and 
following manufactures protocol. To the Master mix, we added 10 pL o f 5X Green Go 
Taq reaction buffer, 5pL of the cDNA product obtained from the Reverse Transcriptase 
Kit and 5 pL of each o f the different primers (COX-2, MMP-3, Hep27, P-Actin) 
(QIAGEN, Valencia, CA). The cDNA is then placed in the Multistep 111 Thermostatic 
Circulator (Amersham Biosciences, Piscataway, NJ) and first denatured for 2 m inutes at 
95 °C. After the first denatured step the cDNA is amplified at 95 °C for 30 seconds, 
annealed at 55 °C for 45 seconds and the extension cycle was conducted for 60 seconds at 
72 °C. This step o f polymerization was repeated for 32 cycles. The final extension 
temperature is 72 °C for 5 minutes and then samples were kept at 4 °C until removed 
from instrument (Multistep 111 Thermostatic Circulator), then stored at -20 °C. The 
amplified products were then electrophoresed on 1 % agarose gels for Ih  or until loading
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dye reached the bottom o f the gel. The gel is then stained in 0.5 pg/mL ethidium bromide 
(Sigma-Aldrich) and visualized with a UV illumination.
3.12 ELISA Determination o f COX-2, MMP-3 and PGE2 
M DA-M B-231 (250,000) cells or SD231RD2 (400,000) were seeded into a 150 cm^ 
flask maintained with a total volume o f 20 mL o f MEM cell culture medium. The 
resistant line (SD231RD2) was also supplemented with 400 pL o f 0.0005 mM stock o f 
doxorubicin, for a final concentration o f 0.01 pM  doxorubicin. After 5 days o f 
incubation, the media was collected from the flask and put into 50 mL conical tube and 
centrifuged at room temperature for seven minutes at 1,500 rpm. The supernatant was 
collected and concentrated using a centrifuge filter device o f 10-20 kDa (PALL). The 
adherent cells were rinsed three times with PBS, each rinse was discarded. Following the 
washing procedure, 5 mL o f PBS was added to the flask and cells were scraped and 
transferred to a 15 mL conical tube. The cell solution was centrifuged at 1,500 rpm at 
room temperature for seven minutes and the resulting supernatant was discarded. The 
cells were lysed with 500 pL of cold RIPA cell lysis buffer (Assay Designs, Ann Arbor, 
M l), 20 pL/mL phosphatase, 20 pL/mL protease and 10 pL/mL EDTA (Pierce). The tube 
was placed on ice and then gently shaken for 5 minutes on a plate shaker. The cells were 
then centrifuged at 14,000 x g for 15 minutes at 4 °C, then supernatant was collected and 
stored at -20 °C until further analysis. To determine COX-2 expression, the cell lysate 
was used for COX-2 ELISA (Assay Designs, Ann Arbor, MI), according to manufactures 
instructions. To determine MMP-3 and PGE2, cell culture media was used for MMP-3
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ELISA (Invitrogen, Carlsbad, CA ) and PGE2 ELISA (Assay Designs, Ann Arbor, MI), 
according to the manufacturer’s instructions.
3.13 Cell Cycle Analysis 
To determine cell cycle phase distribution following treatment o f the six day assay, 
cells were harvested, and a cell pellet was obtained by centrifuging the cell solution at 
room temperature for seven minutes at 1,500 rpm. Cells were washed with 5 mL PBS, 
centrifuged and resuspended in 100 pL of PBS. To fix the cells, 1 mL o f cold 95% 
ethanol was added slowly while shaking the sample gently. Samples were then stored at 4 
°C for at least 24h before staining. To analyze the cells, propidium iodide staining was 
carried out. Fixed cells were washed with 2.0 mL of PBS and incubated with 0.1 mL 
Triton X 1% buffer and 0.1 mL RNase at 1 mg/mL for 10 min at room temperature. 
Propidium iodide stain (0.2 mL) at a concentration o f 100 pg/mL was added and cells 
were incubated for 30 min in the dark at room temperature. Samples were analyzed on the 
Becton Dickinson FACSCalibur (Becton Dickinson, USA) and results were evaluated 
using ModFit LT Version 3.0 (verity Software House, Topsham, ME).
3.14 Live/Dead Viability Assay 
. Following completion o f the six day assay, cells were scraped in the maintenance 
media and the cell suspension was centrifuged for seven minutes at room temperature at
1,500 rpm. The supernatant was then discarded and the remaining cell pellet was washed 
with 5 mL of PBS. The washed pellet was centrifuged again, and the supernatant was 
discarded. The cell pellet was then re-suspended in 100 pL o f PBS and 2 pL o f the
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working solution o f SYTOX green (Molecular Probes, USA) and 2 pL of the working 
solution o f C l2 resaurzin (Molecular Probes, USA). Samples were then incubated for 15 
min at room temperature, 200 pL o f PBS was added, then placed on ice and analyzed 
immediately using the Becton Dickinson FACSCalibur (Becton Dickinson, USA) and 
results were evaluated using ModFit LT Version 3.0 (verity Software House, Topsham, 
ME).
3.15 Fluorescence Microscopy 
On the sixth day o f  the six day viability assay, SD231RD2 and M DA-M B-231 cells 
were seeded into a 4-well chamber slide plate, with 40,000 cells/well and a total volume 
o f 0.5 mL. The cells were incubated for 24h to allow cell density to reach 70 to 80% 
confluency. After 24 h media was removed and wells were washed with PBS and stained 
with 0.5 mL o f Hoechst (2 pg/mL) and 0.5 mL o f propidium iodide (10 pg/mL) diluted in 
PBS. The wells were incubated for 15 minutes and the images were acquired.
A bright field image was obtained visualizing cells with a phase lamp. 
Apoptotic cells were identified using a mercury lamp with an excitation wavelength o f 
300 -500 nm and an ultraviolet filter with an emission wavelength o f 435-485 nm. Cells 
that have taken up the Hoechst stain are identified as apoptotic. Necrotic cells were 
identified using the mercury lamp and a green filter with an emission wavelength o f 600- 
660 nm. A positive finding appeared red due to the presence o f the propidium iodide stain 
within the cell. The images were taken with a Photometries Cool Snap CCD camera 
attached to a Nikon Eclipse TE2000-U microscope (Nikon Inc. Melvile, NY) and 
analyzed using MetaVue software (Meta Series 6.0/6.1, Universal Imaging Corporation).
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To determine the percent o f apoptosis or necrosis, the following equation was 
used:
Number o f positive apoptotic/necrotic cells x 100%
Total number o f cells in the bright field
The three areas o f the wells imaged were randomly selected and were scanned in each o f 
the control and treated wells (n=3).
3.11 Statistical Analysis 
Results were expressed as mean ± standard error o f the mean (SEM), with groups 
consisting o f three observations and each experiment preformed two or three times.
Determination of the Standard error o f the mean:
aMap
a m ra g t o f  the ca d ra i
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CHAPTER 4
FINDINGS OF THE STUDY 
4.1 Analysis o f Results 
To determine the efficacy o f doxorubicin and cisplatin on the breast cancer cell lines 
M DA-M B-231 and MCF-7, colony formation assays were performed to monitor 
proliferation. MCF-7 cells were exposed to a 1 h  treatment o f cisplatin at varying 
concentrations. The results o f the survival gave a LD50 o f 2.20 x 10'"^  M for cisplatin 
(Figure 7A). By expanding the area between 100 and 1000 pM, a more precise LD 50 was 
achieved. The expansion results in a LD 50 o f 4.27 x 10 '* M for cisplatin. Other LD 50 
values in our lab with cisplatin and MCF-7 with n=2 trials gave an L D 5 0  of 3.13 x lO '^M.
Doxorubicin survivals with M DA-M B-231 and MCF-7 are shown in Figure 8 A and 
8 B, respectively. M DA-M B-231 was exposed to a 1 h treatment o f doxorubicin at 
varying concentrations. The results o f the survival gave an LD 50 o f  1.85 x 10'^ M for 
doxorubicin (Figure 8 A). However, we find that MCF-7 cells exposed to varying 
concentrations for 1 h are slightly less sensitive to doxorubicin with an LD 50 o f
6.85 X 10'^ M (Figure 8 B). M BA-M D-231 clonogenic survivals using cisplatin were not 
performed, because their LD 50 values were determined previously by Van Vo to be 
3.33 X 10"*M(21).
27
120i120i
MCF-7 parental ♦  MCF-7 parental
0 -ho-H t
Figure 7. Clonogenic survival with Ih  treatment cisplatin and MCF-7. Cell survival was
measured and compared to control cells after a 1 hour exposure to varying concentrations 
of cisplatin (M). The above figure A and B represents one trial each. Colonies were 
stained with crystal violet and viability was measured by counting colonies and 
comparing to the number o f colonies in the control sample. A colony is a group of cells 
with n > 50.
Determining the LD 50 o f  these drugs helped distinguish which concentrations should 
be used to develop the resistant cell lines. The most appropriate concentrations to begin 
with were two concentrations that were above the L D 5 0 ,  a value close to the L D 5 0  and two 
concentrations below the L D 5 0 .  Preparation o f the M DA-M B-231 resistant cell line 
required six months o f continuous exposure to 10'^ M doxorubicin; the resistant cell line 
is referred to as SD231RD2. The naming convention utilizes the researcher’s initials, SD; 
a portion o f the wild type cell line nomenclature, 231 from the full name M DA-M B-231 ; 
an indication o f resistance to doxorubicin, RD; and the colony number harvested.
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specifically “2 ” for the second colony harvested from the population that was exposed to 
continuous treatment.
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Figure 8 . Clonogenic survival with Ihr treatment doxorubicin. Cell survival was 
measured and compared to control cells after a 1 hour exposure to varying concentrations 
o f Doxorubicin (M). Figure A represents three trials for MDA-MB-231, whereas Figure 
B represents one trial for MCF-7. Colonies were stained with crystal violet and viability 
was measured by counting colonies and comparing to the number o f colonies in the 
control sample. A colony is a group o f cells with n=50 or greater.
The MCF-7 resistant cell line prepared also required approximately six months of 
continuous exposure to 10'^ M, 10'^ M and 10 '* M cisplatin. Although more than one 
resistant line was produced with cisplatin, the naming convention described previously is 
applicable to this cell line with M7 representing the original cell line nomenclature, RC 
indicating resistance to cisplatin and the final number indicated the colony harvested from 
the population that was exposed to continuous treatment. The resistant cell lines
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distinguished as SDM7-RC16 through SDM7-RC22 are colonies derived from  10'^ M 
concentrations o f cisplatin exposure; SDM7-RC9 through SDM7-RC15 were lines 
developed from exposure to 10'^ M concentrations o f cisplatin exposure and SDM7-RC7 
and SDM7-RC8 were lines developed from exposure to 10'“* M concentrations o f cisplatin 
exposure (Table 1).
Resistant Cell Line Resistant to Anticancer Agent Proliferation Status
SDM7-RC7 & SDM7- 
RC8 100 gM Cisplatin Proliferation Ceased
SDM7-RC9-SDM7-
RC15 1 pM Cisplatin Proliferation Ceased
SDM7-RC16-SDM7-
RC22 0.1 pM Cisplatin Proliferation Ceased
SD231RD2 0.01 pM Doxorubicin
Ongoing
Proliferation
SDM7-RD 0.01 pM Doxorubicin Never Developed
SD231RC 1 pM Cisplatin Never Developed
Table 1. Report o f resistant cell lines produced and proliferation status. Table indicates 
the resistant cell line name, concentration o f anticancer agent the line is resistant too and 
also reports if  the cell line is still proliferating or if  the cell line is not viable. The cell 
lines in which the proliferation ceased was due to a change in fetal bovine serum.
To produce evidence to support whether the cell lines are resistant by increased 
viability o f the resistant line when compared to wild type, AlamarBlue, clonogenic 
survivals, and 6  day viability assays were performed. AlamarBlue was the first test 
preformed. The first resistant cell line produced SDM7RC had many clones produced 
with MCF-7 and cisplatin at 10 '*, 10'® and lO'^M.
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The prediction was that the lO '* colonies would be more resistant to cisplatin when 
compared to wild type, followed by 10 ® and 10'^ colonies. However, when tested with 
AlamarBlue we did not see a trend. At the highest cisplatin concentration (1000 pM) the 
wild type cell line demonstrated a percent survival o f 29.91 ± 1.22 %. The resistant lines 
at lO'^M cisplatin, SDM7-RC7 and SDM7-RC8, produced survivals of 33.54 ±1.09 and
28.16 ± 0.41 %, respectively. SDM7-RC14 & RC15 at 10'®M cisplatin (Figure 9) and 
SDM7-RC9 & RC13 (Figure 10) produced an increase in survival of approximately 20% 
when compared to wild type. Both cell lines at 10'^ produced an increase o f survival o f 
10% (Figure 9-10).
Comparing the resistance capabilities o f each cell line that were predicted to be 
resistant to the same concentration o f drug revealed that not all lines are equally resistant 
to cisplatin. SDM7-RC18 and SDM7-RC17 are not resistant to 10'^ M cisplatin, while 
SDM7-RC19 and SDM7-RC20 are slightly resistant by 10% (Figure 10).
W hen the duplicate test was performed one month later, the resistant capabilities of 
the cell lines diminished slightly. RCM7-RC15 and RCM7-RC9 survival was only 10% 
higher than wild type (Figure 11). These resistant lines were also starting to diminish 
slowly and were not proliferating at their rates previously observed.
Clonogenic survivals were preformed to test the sensitivity o f AlamarBlue and to 
confirm if the resistant MCF-7 cell lines were truly demonstrating resistance. SDM7- 
RC13 and SDM7-RC14 demonstrate a higher sensitivity to the cisplatin then wild type, 
clearly indicating no resistance (Figure 12). SDM7-RC7 and SDM7-RC20 show a 20% 
higher resistance when cells are treated with a concentration o f 1 0 0  pM  cisplatin 
compared to wild type. When exposed to higher concentrations o f 1000 pM  cisplatin, all
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cell lines responded the same way and produced no colonies. The resistant MCF-7 cell 
lines stopped proliferating and died out completely due to the use o f a different 
manufacturer’s fetal bovine serum. Therefore, no further tests were performed.
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Figure 9. AlamarBlue assay using wild type MCF-7 and resistant cell lines. Cell survival 
was measured and compared to control cells after a 24 h exposure to 100, 500 and 1000 
pM  cisplatin. Figure A represents resistant lines from lO '^M cisplatin, B represents 
resistant lines from 10'®M cisplatin and C represents resistant lines from lO'^M cisplatin. 
Cell viability was measured by staining cells with AlamarBlue and measuring absorbance 
at 595nm using a spectrophotometer. n= l trial and triplicate readings with SEM.
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Figure 10. Alamar Blue Assay using wild type MCF-7 and resistant cell lines. Cell 
survival was measured and compared to control cells after a 24 h exposure to 100, 500 
and 1000 pM cisplatin. Figure A represents resistant lines from 10'®M cisplatin and B 
represents resistant lines from lO'^M cisplatin. Cell viability was measured by staining 
cells with AlamarBlue and measuring absorbance at 595nm using a spectrophotometer. 
n= l trial, and triplicate readings with SEM.
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Figure 11. AlamarBlue assay using wild type MCF-7 and resistant cell lines. A duplicate 
cell survival was measured and compared to control cells after a 24 h exposure to 100, 
500 and 1000 pM  cisplatin. Figure A represents resistant lines from 10'"*M cisplatin, B 
represents resistant lines from 10'®M cisplatin and C represents resistant lines from lO'^M 
cisplatin. Cell viability was measured by staining cells with AlamarBlue and measuring 
absorbance at 595nm using a spectrophotometer. n= l trial, and triplicate readings with 
SEM.
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Figure 12. Clonogenic survival with Ih  treatment cisplatin using MCF-7 resistant cel 
lines. Cell survival was measured and compared to control cells after a 1 h exposure to 
varying concentrations o f Cisplatin (pM). The above figure represents one trial. Colonies 
were stained with crystal violet and viability was measured by counting colonies and 
comparing to the number o f colonies in the control sample. A colony is a group o f  cells 
with n=50 greater.
The last resistant line, developed from the parental line MDA-MB-231, which was 
exposed to 10'* M doxorubicin. We tested drug exposure for 24 h and 48 h using 
AlamarBlue assay, and found SD231RD2 slightly more resistant to exposure to 
doxorubicin at both 24 and 48 h. At all drug concentrations tested, SD231RD2 was m ore 
resistant by approximately 10% when compared to wild type (Figurel3).
To confirm resistance clonogenic survivals were used, which is a more sensitive assay 
in comparison to AlamarBlue assay. Wild type MDA-MB-231 and SD231RD2 were 
exposed to Ih  treatments o f doxorubicin, the wild type survival is shown in Figure 8  and 
the resistant line survival is shown in Figure 14. The LD50 o f SD231RD2 was foimd to be 
3.75 X 10'* M (0.0375 pM). This value is compared to the parental who gave an LD5 0  o f
1.85 X 10'^ M doxorubicin (0.185 pM). Since this survival did not confirm resistance, 
exposure time of doxorubicin was increased to 24 h for both the resistant and wild type
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cell line (Figure 15). W ith the 24 h exposure to doxorubicin, we see a 5 fold difference in 
the LD50 values. Wild type is more sensitive to doxorubicin at a 24 h exposure (LD50 of
1.16 xlO'^ M) while SD231RD2 is more resistant with an LD50 of 5.58 x 10'** M.
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Figure 13. AlamarBlue assay using wild type and resistant M BA-M D-231 cell lines. Cell 
survival was measured and compared to control cells after a 24 (Figure A) and 48 hour 
exposure (Figure B) to varying concentrations o f doxorubicin (pM). Cell viability was 
measured by staining cells with AlamarBlue and measuring absorbance at 595nm using a 
spectrophotometer. The figure represents two trials and triplicate readings with SEM.
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SD231RD2
f  1001 k .
Figure 14. Clonogenic survival with 1 h treatment doxorubicin, using SD231RD2. Cell 
survival was measured and compared to control cells after a 1 hour exposure to varying 
concentrations o f doxorubicin (M). The figure represents one trial. Colonies were stained 
with crystal violet and viability was measured by counting colonies and comparing to the 
number o f colonies in the control sample. A colony is a group o f cells with n=50 greater.
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Figure 15. Clonogenic survival with 24 h treatment doxorubicin, using MDA-MB-231 
and SD231RD2. Cell survival was measured and compared to control cells after a 24 
hour exposure to varying concentrations o f Doxorubicin (M). The figure represents three 
trials. Colonies were stained with crystal violet and viability was measured by counting 
colonies and comparing to the number o f colonies in the control sample. A colony is a 
group o f cells with n=50 greater.
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Figure 16. Six Day Viability Assay using Doxorubicin. MDA-MB-231 wild type and 
resistant cell line SD231RD2 were exposed to a 6  day exposure o f varying concentrations 
of doxorubicin (M). Cell survival was measured by counting cells using a coulter counter 
and comparing to control cell numbers. The figure represents 3 trials, o f triplicate 
readings.
One more assay was performed prior to microarray analysis. The six day assay 
confirmed that the cell line produced was indeed resistant with a 60% difference in 
survival rates when both the resistant cell line and the parental were exposed to a 
concentration o f 0.01 pM  doxorubicin (Figure 16).
To further analyze the extent o f resistance, resistant and wild type cells were either 
treated or not treated with chemotherapeutic agent for six days and analyzed using the 
live/dead viability assay, phase cycle analysis and fluorescence microscopy. For the 
live/dead assay we hoped to see a significant increase in cell viability for the resistant line 
when compared to the wild type. Figure 17 shows the percentage o f cells that are viable, 
injured (which indicates the first step o f apoptosis) or dead. The wild type had 
approximately 2 0 % less viable cells compared to the resistant line with or w ithout drug.
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and when compared to the wild type line without chemotherapeutic agent. The resistant 
line had a slight response within error to the chemotherapeutic agent when compared to 
control cells o f both the resistant line and wild type lines.
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Figure 17. Live/Dead Viability Assay with SD231RD2and MDA-MB-231 cells. Cells 
were harvested on day 6  o f the Six Day Viability Assay. The figure is representative o f  2 
trials. The study demonstrates that after six days o f continuous exposure to doxorubicin, 
the wild type cell line experiences a higher percentage o f injured cells, which is indicative 
o f apoptosis. The resistant line demonstrates a slight increase in the number o f injured 
cells in comparison resistant line control which was not exposed to chemotherapy 
treatment.
In another flow cytometry experiment, phase cycle analysis, cells were collected on 
day six o f a six day exposure to doxorubicin. The wild type cell line, M DA-M B-231 
which was treated for six days, displayed a block in G2/M phase when compared to the 
untreated line. This is evident by a decrease in GO/Gl and S phases, which leads to the 
subsequent increase in G2/M phase (Figure ISA). On the other hand, there was no block 
in the any phase o f the cell cycle seen for the resistant treated cell line, SD231RD2 when 
compared to both the resistant line that was untreated (Figure 18B) and the parental wild
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type line M DA-M D-231. The apoptotic peak had an increase o f 20% in the treated wild 
type when compared to wild type control and resistant lines.
Fluorescence microscopy was used to distinguish between an apoptotic or necrotic 
mechanism of death. Again cells were harvested on day 6  after exposure to 0.01 pM 
doxorubicin for six days, seeded, and incubated for 24 h. Cells were stained with Hoechst 
and propidium iodide to visualize apoptotic and necrotic cells. The wild type line 
indicated that the mechanism o f death is apoptotic due to the substantial increase in 
apoptotic cells upon treatment with the drug (Table 2). However, this trend is not 
observed with necrosis. There was no increase in necrotic cells when compared to 
control. The resistant cell line did not point to a specific mechanism of death, but there 
were more apoptotic cells than necrotic. Microscopic images o f the cells can be seen in 
Figure 19A, show the differences in the wild type line that is untreated and treated for 6  
days. The images clearly demonstrate the effects o f 6  day exposure by a reduced number 
o f cells and illustrate changes in the morphology of the wild type cell line (Figure 19B). 
The resistant line did not demonstrate the same trend. The resistant line when exposed to 
no drug (Figure 19C) appears to have no morphological changes when compared the 
resistant line that was exposed to drug (Figure 19D). Also, there were no differences in 
cell proliferation o f the exposed resistant line when compared to control (non-treated 
resistant). It should also be pointed out that the parental line (not exposed to drug) and 
resistant line (exposed or unexposed) did not appear to have a difference in morphology.
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Figure 18. Cell cycle analysis o f M DA-M B-231 and SD231RD2. Cells were harvested 
after a six day exposure to 0.01 pM  doxorubicin than analyzed by flow cytometry. The 
wild type cell line demonstrates a block in the G2/M phase (A), while the resistant line 
SD231-RD2 does not experience a block in any phase o f the cell cycle when compared to 
control resistant cells that were not exposed to drug (B). The figure represents one trial.
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Treatment Percent Apoptosis Percent Necrosis
MDA-MB-231 Control 1.7 ±0.6 0.9 ± 0.2
MDA-MB-231 6 Day 
Exposure (DOX) 16.9 ±4.5 2.0 ± 2.3
SD231RD2 Control 4.3 ± 0.8 0.9 ± 0.1
SD231RD2 6 Day Exposure 
(DOX) 5.9 ± 0.1 1.1 ± 0.8
Table 2. Fluorescence microscopy analysis of MDA-MB-231 and SD231RD2 cells. Cells 
were harvested after a six day exposure to 0.01 pM  doxorubicin than analyzed by flow 
cytometry. The wild type cell line demonstrates a significant increase in apoptosis. While 
the resistant line SD231-RD2 also follows an apoptotic mechanism of death. The data in 
the table is representative of two independent trials.
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Figure 19. Bright field fluorescence microscopy images. Wild type untreated (A), wild 
type treated (B), resistant line untreated (C) and resistant line treated (D) by six day 
exposure to doxorubicin, harvested and incubated for 24 h, and then images were 
obtained.
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The data supports that the resistant cell line produced is resistant to doxorubicin, 
therefore samples o f RNA were sent to the Winber Institute for wild type and resistant 
lines analysis o f gene expression. Genes that were more highly expressed are shown in 
Table 3. The genes o f interest were COX-2 and MMP-3, which had fold changes of
11.96 and 14.93, respectively, in comparison to wild type gene expression levels.
To confirm the microarray data. Western blot analysis was performed to establish a 
baseline for expression o f our proteins o f interest. The first attempt with western analysis 
used 40, 60 and 80 pg o f protein, and our results indicated that neither COX-2 nor MMP- 
3 was present (Figure 20). For the second trial, the protein mass was increased to 120 and 
150 pg and protein standards COX-2 (2 pg), MMP-3 and P-Actin were incorporated. 
However, the presence o f the proteins was not established and the protein standard for 
COX-2 was too strong, which is indicated by the thick band (Figure 21). Also, MMP-3 
standard was not observed. The final attempt used protein masses o f 150 and 200 pg o f 
protein, also a lower concentration for protein standard COX-2 (0.5 and 1 pg) and for 
MMP-3 fresh antibody was made at the strongest concentration. Both protein standards 
were observed along with P-Actin, but the proteins o f interest from the cell lysates were 
still not observed (Figure 22). Since there was no protein expression in western analysis, 
a confirmation o f the microarray analysis is needed to ensure overexpression o f the 
mRNA. Therefore semi-quantitative PCR was performed. The PCR data (Figure 23) 
confirmed the over-expression levels o f the COX-2, MMP-3 and Hep27 (protein not o f 
interest, but still overexpressed). A repeat o f PCR was ran in the presence o f a base pair 
ladder, this is shown in Figure 24. In order to justify the PCR adducts to be valid, loading 
controls such as P-actin and a smaller base pair ladder o f 50-200 was used (Figure 25).
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Gene Names 
(Common)
Fold
Change
Activity Protein Expression
COX-2 
prostaglandin- 
endoperoxide 
synthase 2
11.96
anagen 
blood pressure regulation 
cell motility 
cyclooxygenase pathway 
fatty acid biosynthetic process 
kératinocyte differentiation 
prostaglandin biosynthetic process 
regulation of inflammatory response
cytoplasm
membrane
nucleus
MMP-3 
matrix 
metalloproteinase 3 
(stromelysin 1, 
progelatinase)
14.93
collagen catabolic process 
peptidoglycan metabolic process 
proteolysis
extracellular space 
proteinaceous- 
extracellular matrix
TRIP14 
2-5oligoadenylate 
synthetase-related 
protein p30 (OASL)
17.55
biologicaljjrocess 
immune response 
protein modification process
cytoplasm
nucleolus
HEP27; DHRS2 short- 
chain
alcohol dehydrogenase
18.94
C21-steroid hormone metabolic process 
electron transport 
metabolic process 
negative regulation of progression 
through cell cycle
nucleus
H2A/1 
H2A histone family
19.03
chromosome organization and 
biogenesis 
nucleosome assembly
chromosome
nucleosome
nucleus
G10P2 27.21
biological Jjrocess 
immune response
cellularcomponent
H2B/b 
H2B histone family
36.66
chromosome organization and 
biogenesis 
nucleosome assembly
chromosome
nucleosome
nucleus
T ab le  3. M icro array  analysis. M D A -M B -231 w ild  type cells w ere co m p ared  by
microarray analysis to the resistant line, SD231RD2. The above table shows the ten genes 
that had the largest increase in expression in SD231RD2 cells in comparison to MDA- 
M B-231 wild type cells. The Table also indicates function o f the protein, the activity it 
possesses and where the protein can be found in the cell.
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Figure 20. Western blot analysis o f M DA-M B-231 and SD231RD2 lines. W estern blots 
were looking for the production o f COX-2 and MMP-3 using protein concentrations o f 
40, 60 and 80 pg. Lane one is transfer ladder, followed by wild type cell 40, 60 and 80 pg 
o f protein from left to right in lanes 2-7 duplicate. The next 8-12 lanes are SD231RD2 
with 40, 60 and 80 pg o f protein from left to right in duplicate (80 pg for the resistant line 
was loaded only once in lane 12). P-Actin is used as a loading control.
C O X -2
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Figure 21. Western blot analysis o f MDA-MB-231 and SD231RD2 lines. W estern blots 
were looking for the production o f COX-2 and MMP-3 using protein masses o f 120 and 
150 pg. Lane one is transfer ladder, lane two is either COX-2 or MMP-3 protein standard. 
MDA-MB-231 with 120 pg o f protein (lanes 3-4) and 150 pg o f protein (lanes 5-6) from 
left to right in duplicate. SD231RD2 with 120 pg o f  protein (lanes 7-8) and 150 pg o f 
protein (lanes 9-10) from left to right in duplicate. P-Actin is used as a loading control.
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Figure 22. W estern blot analysis o f MDA-MB-231 and SD231RD2 lines. W estern blots 
were used to determine production levels o f COX-2 and MMP-3 using protein masses o f 
150 and 200 pg. Lane one or two is transfer ladder, followed by COX-2 (lane 2-3) or 
MMP-3 (lane 3) protein standard. M DA-M B-231 with 150 pg (lanes4-5) and 200 pg 
(lanes 6-7) o f protein from left to right in duplicate. SD231RD2 with 150 pg (lanes 8-9) 
and 200 pg (lanes 10-11) o f protein from left to right in duplicate. P-Actin is used as a 
loading control.
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Figure 23. Semi-Quantative PCR o f wild type and resistant cell lines. PCR confirmed 
presence o f mRNA products o f MMP-3, COX-2 and Hep27.
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Figure 24. Semi-Quantative PCR o f wild type and resistant cell lines. PCR confirmed 
presence o f mRNA products o f MMP-3, COX-2 and Hep27. Lane one is a 200-2000 base 
pair ladder, lanes are identified in figure.
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Figure 25. Semi-Quantative PCR o f  wild type and resistant cell lines. PCR confirmed 
presence o f mRNA products o f MMP-3, COX-2 and P-actin. Gel A detection o f COX-2, 
lane 1 is a 50-200 base pair ladder, lane 2 is a 200-2000, lanes 3-5 are MDA-MB-231 in 
volumes o f 2.5, 5 and 10 pL o f cDNA. Lanes 6-8 are SD231RD2 in volumes o f 2.5, 5 
and 10 pL o f cDNA, lanes 9-11 is loading control P-actin for SD231RD2 in volumes o f 
2.5, 5 and 10 pL o f cDNA. Gel B, lanes are identical but detecting MMP-3 instead o f 
COX-2. Lanes 9-11 are loading control P-actin for MDA-MB-231 in volumes o f 2.5, 5 
and 10 pL o f cDNA.
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Also, figure 25 used fresh isolated RNA from SD231RD2 to ensure that the resistant lines 
RNA was not changing with time, to eliminate the factor o f variance in the genome.
To examine lower concentrations o f the proteins COX-2 and MMP-3, ELISA assays 
were performed. Figures 26 and 27 illustrate a typical protein standard curve for COX-2 
and MMP-3, respectively. From the standard curves the results indicate that there is 
slight increase o f both these proteins in the resistant lines compared to the wild type. 
There was no indication o f COX-2 present in the wild type cell line, while there was a 
slight amount o f COX-2 (2 ng/mL) present in the resistant line. The amount o f MMP-3 
present in SD231RD2 was found to be 0.33 ng/mL and the concentration o f MMP-3 in 
the parental line which was 0.059 ng/mL (Table 4). However, all these concentrations are 
below the level o f detection in the kit.
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Figure 26. ELISA standard protein curve for COX-2. The y-axis represents Absorbance at 
450 nm and the x-axis represents concentration o f protein in ng/mL. The unknown 
samples are determined by the linear regression line shown on the graph.
48
2 .0 - = 0 .9967
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Figure 27. ELISA standard protein curve for M M P-3. The y-axis represents Absorbance 
at 450 nm and the x-axis represents concentration o f protein in ng/mL. The unknown 
samples are determined by the linear regression line shown on the graph.
To further analyze these results, we decided to try to inhibit COX-2 even though we 
were not seeing the protein in western analysis or ELISA data. On inhibition on COX-2 
with 50pM  o f indomethacin the LD50 o f  the resistant line is shifted to the left and 
becomes more sensitive to doxorubicin (Figure 28). The LD50 is more indicative o f the 
parental cell line, thereby indicating that sensitivity is restored to the resistant line. To 
confirm that the shift o f  the L D 50  seen in the resistant line was valid due to the inhibition 
o f COX-2 and not due to toxicity o f indomethacin, MDA-MB-231 was exposed to the 
same concentrations o f indomethacin only and to indomethacin plus the LD50 o f 
doxorubicin (rounded to 0.01 pM) to ensure no cell death or shifts in the lethal dose when 
administered with doxorubicin (Figure 29). Also, SD231RD2 was exposed again to 
indomethacin this time using two added controls, a treatment with indomethacin (50 pM )
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o n l y  a n d  a n o t h e r  u s i n g  o n l y  t h e  L D 50  ( u s i n g  a  r o u n d e d  v a l u e  o f  0 . 0 5  g M )  o f  d o x o r u b i c i n .  
T h e  f i g u r e  c l e a r l y  d e m o n s t r a t e s  t h e  s h i f t  i n  t h e  L D 50  w h e n  i n d o m e t h a c i n  i s  a d d e d  ( F i g u r e  
29y
F u r t h e r m o r e ,  w e  a l s o  p e r f o r m e d  a n  E L I S A  a s s a y  o n  t h e  w i l d  t y p e  a n d  r e s i s t a n t  l i n e s  
f o r  P G E 2 ,  a n  e n d  p r o d u c t  o f  C O X - 2 .  A  t y p i c a l  s t a n d a r d  c u r v e  o f  P G E 2  i s  g i v e n  i n  F i g u r e
3 0 .  T h e  d a t a  i n d i c a t e s  t h a t  t h e  w i l d  t y p e  l i n e  p r o d u c e d  1 5 . 9 5  p g / m L  o f  P G E ? ,  h o w e v e r  
t h e  r e s i s t a n t  l i n e  s h o w e d  a  m u c h  h i g h e r  a b u n d a n c e  o f  P G E 2 a t  a  c o n c e n t r a t i o n  o f  3 9 3 . 9 1  
p g / m L ,  t h u s  g i v i n g  a  f o l d  i n c r e a s e  o f  2 5  ( T a b l e  4 ) .
I2O1
SD231RD2 (With Indomethacin) 
MDA-MB-231 parental 24h
80-
60-
40-
20 -
0
9>
F i g u r e  2 8 .  C l o n o g e n i c  S u r v i v a l  o f  S D 2 3 1 R D 2  w i t h  i n h i b i t o r  I n d o m e t h a c i n  ( 5 0  p M ) .  
R e s u l t s  s h o w  t h a t  i n  t h e  p r e s e n c e  o f  5 0  p M  i n d o m e t h a c i n  t h e  L D 50  s h i f t s  t o  t h e  l e f t  a n d  
r e s e m b l e s  t h e  p a r e n t a l  c e l l  l i n e s  L D 50  w h e n  e x p o s e d  t o  d o x o r u b i c i n  ( M ) .  I n d o m e t h a c i n  
a n d  d o x o r u b i c i n  r e m a i n e d  o n  t h e  c e l l s  f o r  2 4 h r s  i n  a  c o m b i n a t i o n  t r e a t m e n t .  R e s i s t a n c e  o f  
t h e  c e l l  l i n e  d i m i n i s h e s .  T h e  f i g u r e  r e p r e s e n t s  o n e  t r i a l .
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Figure 29. Clonogenic Survival o f M DA-M B-231 and SD231RD2 with inhibitor 
indomethacin (50 pM). Results show that in the presence o f 50 pM  indomethacin only 
there is no toxic event occurring when compared to the control for the wild type cell line 
(B) and the resistant line (A). Also when comparing the LDso values o f doxorubicin only 
to the LD50 o f  doxorubicin (0.01 pM) + indomethacin (50 pM) in the wild type line (B) 
there is no difference within error. However, when comparing the LD 50 (0.05 pM ) o f 
doxorubicin only and then in combination with indomethacin for the resistant line (A) we 
find a significant increase in cell death. Combinations concentrations o f indomethacin 
and doxorubicin are seen in the bars represented as concentrations in pM.
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Figure 30. ELISA standard curve for PGE2 where y-axis is B/Bo % and x-axis is 
concentration in pg/mL. The unknown samples are determined by the log regression line 
shown on graph.
Treatment COX-2
(ng/m L)
MMP-3
(ng/mL)
PGE2
(pg/m L)
MDA-MB-231 0.73 0.35 15.95
SD231RD2 2.18 0.62 393.91
Table 4. Wild type and resistant ELISA data for COX-2, MMP-3 and PGE2 . The table 
represents only 1 trial o f duplicate readings.
In summary, it appears that when doxorubicin is added to the resistant cell lines to 
promote apoptosis, there is a protection provided by elevated MMP-3 and COX-2. 
Furthermore COX-2 also stimulates the production o f PGEi, adding more resistance
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against cell death. However, the mechanism o f this process is still unclear. The wild type 
cell line has no over expression o f gene products or proteins, therefore is not protected 
and will undergo apoptosis through programmed cell death (Figure 31).
Doxorubicin
SD231RD2
c o x -2 1 triggers PGE^  j (- - - 3  ( Protected = No apoptosi^
Doxorubicin -
No Over expressed 
genes Apoptosis
Figure 31. Conditions occuring in resistant cell lines vs wild type.
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CHAPTER 5
SUMMARY, CONCLUSIONS AND RECOMMENDATIONS
5.1 Discussion o f Results
The main objectives o f this study were to determine gene expression profiles and 
possible biomarkers for treatment o f resistant breast cancer cell lines by providing data 
relevant to the following tasks:
1) Preparation o f a resistant breast cancer cell line
Determining the LD 50 concentrations o f the drugs o f interest to the wild type cell line 
is the first step in developing a resistant cell line. This value is needed to determine which 
concentrations are required to initiate chronic drug exposure to wild type cells. 
Additionally, the LD50 values o f wild type lines are needed to compare to resistant lines 
once developed to confirm resistance. One research group prepared ovarian carcinoma 
resistant cell lines using an approach similiar to the one described here (22). Other 
research groups exposed cells to a single dose o f 200 nmol/L for 24 h then harvest the 
remaining cells. To categorize these cells as resistant reseachers performed modified 
colony formation assays using a drug treatment time o f 24 h and cultured for 12 days, 
which is very similar to the technique used in this study (23). Purchased cell lines that
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h a v e  t a r g e t  g e n e  k n o c k o u t s  t h a t  a r e  k n o w n  t o  c a u s e  r e s i s t a n c e  t o  a n t i c a n c e r  a g e n t s  h a v e  
a l s o  b e e n  u s e d .
F r o m  t h e  r e s u l t s ,  p a r e n t a l  M C F - 7  a n d  M D A - M B - 2 3 1  b r e a s t  c a r c n i o m a  h a v e  v e r y  
s i m i l a r  r e s p o n s e  t o  a  I h  t r e a t m e n t  w i t h  c i s p l a t i n  g i v i n g  a n  L D 50  o f  3 . 1 3  x  1 0 ' " ^ M  a n d  3 . 3 3  
X 1 0 ' " ^ M ,  r e s p e c t i v e l y  ( F i g u r e  7 ) .  A s  a n  i n i t i a l  c o m p a r i s o n  w e  c h o o s e  a  k n o w n  e f f i c a c i o u s  
c o n c e n t r a t i o n ,  t h e  L D 5 0 ,  t o  d e t e r m i n e  c a p a c i t y  f o r  r e s i s t a n c e .  T o  d e v e l o p  t h e  r e s i s t a n t  c e l l  
l i n e s  w e  m a i n t a i n e d  t h e  c e l l s  i n  d r u g  c o n c e n t r a t i o n s  l e s s  t h a n ,  e q u a l  t o  a n d  h i g h e r  t h a n  
t h e  L D 5 0 .
H o w e v e r ,  w i t h  r e s p e c t  t o  d o x o r u b i c i n ,  t h e  c e l l  l i n e s  b e h a v e  s l i g h t y  d i f f e r e n t  i n  
c o m p a r i s o n  t o  c i s p l a t i n .  M C F - 7  i s  a  E R ^  c a r c i n o m a  a n d  w a s  s l i g h t y  m o r e  r e s i s t a n t  t o  
d o x o r u b i c i n ,  g i v i n g  a  L D 50  o f  6 . 8 5  x  1 0 ' ^  M  w h i l e  M D A - M B - 2 3 1  w a s  m o r e  s e n s i t i v e ,  
g i v i n g  a n  L D 50  o f  1 . 8 5  x  1 0 ' ^  M  ( F i g u r e  8 ) .  S i m l a r  v a l u e s  a r e  r e p o r t e d  i n  t h e  l i t e r a t u r e  
( L D 50  f o r  d o x o r u b i c i n  t r e a t m e n t  i n  M D A - M B - 2 3 1  c e l l s  r e p o r t e d  a s  0 . 2 5  x  l O ' ^ M )  ( 2 3 ) .  
A g a i n ,  t h e  M D A - M B - 2 3 1  r e s i s t a n t  l i n e s  w e r e  d e v e l o p e d  w i t h  t h e  s a m e  m e t h o d  a s  t h e  
M C F - 7  r e s i s t a n t  l i n e s .
T h e  f i r s t  t e c h n i q u e  u s e d  t o  v e r i f y  r e s i s t a n c e  w a s  m i t o c h o n d r i a l  d e h y d r o g e n a s e  
a c t i v i t y  a s s a y .  H o w e v e r ,  t h e  r e s u l t s  d i d  n o t  s u p p o r t  p r e d i c t e d  r e s i s t a n c e .  T h e  p r e d i c t i o n  
w a s  t h a t  r e s i s t a n t  M C F - 7  c a r c i n o m a  e x p o s e d  t o  l O  ' ^ M  c i s p l a t i n  w o u l d  h a v e  t h e  h i g h e s t  
d e g r e e  o f  r e s i s t a n c e ,  f o l l o w e d  b y  c e l l s  e x p o s e d  t o  l O ' ^ M  t h e n  l O ' ^ M  c i s p l a t i n .  T h i s  t r e n d  
w a s  n o t  s e e n  i n  t h e  d a t a ;  M C F - 7  c e l l s  e x p o s e d  t o  l O ' ^ M  c i s p l a t i n  h a d  a  h i g h e r  d e g r e e  o f  
r e s i s t a n c e  ( F i g u r e s  9 - 1 1 )  i n  c o m p a r i s o n  t o  c e l l s  e x p o s e d  t o  1 0 ' " * M  c i s p l a t i n .  I n  
a l a m a r B l u e  a s s a y s  c o n d u c t e d  w i t h  t h e  w i l d  t y p e  M D A - M B - 2 3 1  a n d  r e s i s t a n t  c e l l  l i n e s ,  
s u r v i v a l  w a s  o n l y  1 0 %  h i g h e r  i n  t h e  r e s i s t a n t  l i n e  t h a n  t h e  w i l d  t y p e  a t  e v e r y  t e s t e d
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concentration (Figure 13). To further test the results obtained from the alamarBlue assay, 
clonogenic survivals were conducted as a measure o f resistance.
In the clonogenic survivals using MCF7 wild type and resistant lines, at a 
concentration o f 100 gM  cisplatin, there was an inerease in survival o f 40% in the 
SDM7-RC7 and SDM7-RC20 lines whieh are resistant to 10"* and 10‘^ M cisplatin, 
respectively. However, there was not a significant shift in the LD 50 eoncentrations 
indieating that there is limited or no resistanee to the drug (Figure 12). It was unfortunate 
that no further testing eould be performed with these resistant lines beeause o f their 
tenuous growth patterns. The unstable growth patterns oeeured because the vendor used 
for fetal bovine serum (FBS) was changed from Gibco FBS (Invitrogen) to PAA FBS 
(PAA laboratories, USA). This change in serum instantly eaused deereased eell 
proliferation and changes in morphology in resistant as well as parental cell lines. Cells 
were maintained in this serum for three months before returning to the origianl FBS 
vendor, Gibco. MDA-MB-231 developed into colonies in PAA and were not affeeted to 
the same degree as MCF-7 eareinoma, and were suecessftilly adapted from the PAA FBS 
to the Gibco FBS.
M DA-M B-231 resistant lines were also tested by elonogenie survials. After a 1 h 
exposure to doxorubicin, there was no differenee in the LD50 between the resistant and 
wild type eell lines (Figure 14). The exposure time of drug treatments were inereased to 
24 h, hoping that an inereased exposure would not affeet the resistant line but would shift 
the LD50 o f  the parent line. After a 24h exposure, the resistant line had a 5 fold shift in the 
LD50 towards resistanee when eompared to wild type (Figure 15). These results are
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similar to data reported in another study in which a shift in the LDso in addition to 
inereased surival at higher eoneentrations were observed (23).
To test both parental and resistanee lines with confinons exposure to doxorubiein, a 
six day viability assay was employed. The results o f this assay provided the strongest 
support for resistanee. At day 6 and 0.01 pM  doxorubiein, the resistant line had a survival 
o f 80% eompared to 20% survival for the parental line under the same eonditions 
(Figure 16). This shows a 60% differenee in survival response to eontinous drug 
exposure. It is predieted that if  the assay was prolonged to 9, 12, and ,15 days then the 
parental cell line would have 0% survival while the resistant line would eontinue to 
survive and proliferate.
While RNA samples were being proeessed by the W inber Research Institute, further 
testing was performed to examine the extent o f damage to the parental cell line and 
resistant line on day 6 o f the six day assay. A live/dead assay was employed to determine 
the population o f injured, dead and living eells on these cell populations. After six days o f 
eontinuous treatment, the resistant lines had the same levels o f living, injured and dead 
cells as the parental which had not been exposed to drug. This data indicated that the drug 
had little effect on the resistant eell line at the given eoneentration. However, the parental 
line that was treated for six days with 0.01 pM  doxorubicin showed 40% o f the cell 
population being injured and in the first stage o f apoptosis (Figure 17). The ability o f the 
resistant eell line to tolerate eontinuous drug exposure without injury is further supported 
by cell cycle analysis where we see that wild type cells exposed to treatment undergo a 
bloek in G2/M and a 20% inerease in eells undergoing apoptosis. Comparatively, the 
resistant line shows no ehanges in eell cycle and continued cell eycle progression,
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indicating that these cells are not affected by drug exposures (Figure 18). Flourescence 
microscopy was employed to determine whether cell death is occuring by the apoptotic or 
nercrotic pathway. According to the results, the wild type cell line dies by the apopotic 
pathway when exposed to a six day continuous treatment o f doxorubicin. However, the 
resistant cell line experienced little cell death but also had a slightly higher percentage o f 
cells in the apoptotic pathway (Table 2). The images in Figure 18 demostrate the parental 
morphology changes which is consistent with reduced proliferation. It is interesting that 
there is no morophology changes in the resistant line compared to the parental. The only 
change is the rate o f proliferation which is slightly lower when compared to wild type.
1. Determine by microarray analysis which genes are overexpressed in the resistant 
cancer cell line compared to wild type.
Microarray analysis gave us a total o f 712 differently expressed proteins. We decided 
to focus on genes in the resistant population whieh were over expressed by two fold or 
higher in comparison to the wild type. We identified 528 genes that were over expressed 
at this level. We isolated the top ten genes that were overexpressed (Table 3) and o f these 
ten genes we chose two targets to investigate further. These genes were COX-2 and 
MMP-3 which had fold differences o f 11.96 and 14.93, respectively.
COX-2 is part o f arachidonic acid metabolism which occurs in the immune system 
and the brain. Inflammation increases COX-2 expression which results in the enhanced 
production o f PGE2 (24). Prostaglandin synthesis begins with phospholipase (PLA2) 
mediated release o f arachidonic acid. COX-2 converts arachidonic acid into PGH?, which 
is then metabolized to many Prostaglandins (PGs), including PGE? (Figure 6). COX-2 has
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variable expression in eomparison to COX-1 and is highly expressed in eells experieneing 
stress whereas COX-1 is constitutively expressed. These different eyelooxygenases also 
have different biologieal functions in the eell (25). COX-2 is a protein o f interest given 
that induced levels o f COX-2 induee genomie instability in a normal breast line 
(MCFIOA) and genomie instability is one o f the hallmarks o f caneer. Three downstream 
targets o f COX-2 aetivity that have a role in metastasis are found to be urokinase 
plasminogen aetivator, interleukin 8 (IL-8), and interleukin 11 (lL -11). COX-2 mediates 
these events through the P13-kinase/Akt signalling pathway. It is also found that COX-2 
induees expression o f the anti-apoptotie protein Bcl2, whieh is known for eausing drug 
resistanee in many earcinomas to a variety o f anticancer agents, thus providing a rationale 
for doxorubiein resistanee in the eancer initiating phenotype (26).
Matrix metalloproteinases, MMP-3 (stromelysin) degrades several extraeellular 
matrix molecules (ECM), sueh as eartilage proteoglyean and type II collagen. It is known 
that interleukin-ip, a proinflammatory cytokine, induces expression o f MMP-3 and 
prostaglandins (27). MMP-3 over expression in both MCF-7 and M DA-M B-231 eells 
leads to inereased eell numbers and tumor volumes. The presenee o f MMPs in tumors can 
lead to complex treatment ehallenges as these proteases are able to promote or impede 
tumor relevant processes such as proliferation, apoptosis, angiogenesis and metastasis 
(28). The mechanism for MMP-3 induction and subsequent increased resistanee is still 
unelear. Although mieroarray results indieated over expression o f RNA, protein over 
expression was not detected in Western blot (Figure 20-22) or ELISA assays (Table 4).
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2. Identify the pathway or mechanism in which these genes o f interest are involved;
One reason for identifying differential gene expression in resistant cells is to identify 
mechanisms and cellular functions that mediate resistance. Since the genes COX-2 or 
MMP-3 were not indentified in W estern blot analysis (Figures 20-22), ELISA assays, a 
more sensitive technique were used. However, the ELISA results are similar to Western 
blot analyses, as there was no COX-2 or MMP-3 expression in the wild type carcinoma. 
The limit o f the detection o f the COX-2 ELISA kit was 2.15 ng/mL, while the limit o f 
detection for the MMP-3 ELISA was 0.62 ng/mL. From Table 4, the concentrations o f 
COX-2 and MMP-3 that are presented for the parental line are negligible because the 
values are below the detectable limits o f these assays. The resistant line concentrations o f 
these genes are just above the level o f  detection o f these assays; therefore these values are 
not reliable and cannot conclude any relevance.
To test for COX-2 up-regulation, the measurement o f eicosanoid production can 
demonstrate whether the protein is actively inducing product formation. PGE? was tested 
due to its putative role in causing resistance. PGE? is known to stimulate angiogenesis, 
invasiveness and inhibit immune surveillance (28). ELISA assays were performed to 
determine if  over expression o f COX-2 would cause an increased level o f PGE2 . The 
results indicated a 25 fold increase in the production o f PGE2 when compared to the wild 
type cell line (Table 4).
To further investigate the mechanisms in which the process o f  up regulation o f PGE2 
is caused in the resistant cancer cell line, SD23IRD2, microarray data was examined for 
genes that are related to the arachidonic acid metabolism. The PLA2 gene is responsible 
for regulation o f the enzyme phospholipase and therefore stimulation in the production
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arachidonic acid. An increase in this gene could account for the increase in PGE2 that is 
shown in the resistant line (because o f simple metabolism an inerease in an enzyme 
requires synthesis o f more reaetant, therefore produet build-up). However, the mieroarray 
data shows a deerease in the PLA2 gene in the resistant line with a fold differenee o f 0.45 
when eompared to the parental eell line. Also COX-1 was not reported in the mieroarray 
analysis o f being over or under expressed. This proposes that it is solely the aetion o f 
inereased levels o f COX-2 that is stimulating the production o f PGE2 .
COX-2 expression is an important faetor for angiogenesis. Angiogenesis is mediated 
by migration and proliferation o f the host endothelial eells and is a required for tumor 
growth. Vascular endothelial growth faetors (VEGF), transforming growth faetor (TGF), 
basie fibroblast growth faetors (FGF) and ehemokines (IL-8) are implieated in 
angiogenesis in lung eancer (29). Mieroarray data for SD231RD2 indieates that the genes 
VEGF, TGF are present and are overexpressed in this study by 2.3 fold, while FGF is 
inereased by 4.2 fold. Thus, indicating that the cells are capable o f performing 
angiogenesis. Also it has been shown by Patel and Chiplunkar that in lung eaneer PGE2 
ean also inerease eyclin D1 and VEGF through Wnt signalling. This can also contribute 
to the inerease seen in VEGF. Epidermal growth faetor reeeptor (EGER) also needs to be 
increased for the production o f tumors, and is seen to have a 2.5 fold increase in the 
mieroarray data o f SD231RD2.
Extracellular matrix proteins (ECM) are important in tumors for metastasis. MMP-3 
was shown to be over expressed in the mieroarray data o f SD231RD2 resistant line. 
COX-2 was demonstrated to up-regulated ECM genes sueh as MMP-3 and laminin 5,
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proteins involved in migration and invasion (29). The data indicates that lam inin 5 is a 
subunit o f the gene LAMA3 which is overexpressed 4.4 fold in this study.
MDR-1 was also found in this study to be increased by a 2.2 fold difference when 
compared to the wild type cell line. Drug resistance often involves MDR-1 which 
encodes a transmembrane glycoprotein p-170 (P-gp). This protein is responsible for 
protecting cancer cells by pumping out cytotoxic agents, such as doxorubicin out o f the 
cytoplasm and making chemotherapy ineffective (30).
4. Determine if an inhibitor o f these genes will restore sensitivity to the anticancer
agent in the resistant line.
Targeted inhibitions o f COX-2 and PGE? are regarded as potential strategies to 
prevent the presence or progress o f eancers. However, there is risk associated with the 
inhibition o f COX-2. Development o f cardiovascular disease has been associated with 
using the inhibitor o f COX-2, celecoxib, (originally developed for arthritis and pain) for 
the treatment o f lung cancer, but it is still being used sinee it has been shown to induce 
apoptosis in lung caneer (29). Celeeoxib has also been shown in MDA-MB-231 cells to 
enhance the intraeellular aeeumulation o f doxorubiein, possibly via m odulation o f  NF-kB 
activity (30). Ciglitazone is an inhibitor o f COX-2 and has been used in a variety o f 
eareinoma trials (31). Other inhibitors include: nonsteroidal anti-inflammatory agents 
(NSAIDS) and indomethacin, a non-specific COX inhibitor. Doses o f 100 to 150 mg per 
day o f  indomethaein are used to treat rheumatoid arthritis for a period o f  4-6 weeks. The 
eomparable eoncentrations used in- vitro are 50-300 pM  (32). Sinee indomethacin is 
known to reduce invasion and metastasis in breast eareinoma, indomethacin was used to
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inhibit COX-2 activity in our resistant cancer cell line. Upon treatment with 
indomethacin, the resistant line experienced increased sensitivity to doxorubicin, giving 
an LD 50 concentration of 2.04 x lO'^M for doxorubicin. This value is similar to the 
parental line with an LD 50 of 1.16 x 10'^ M for doxorubicin (Figure 28). This indicates 
that inhibited COX-2 activity through the use o f an inhibitor may reverse the resistance 
and restore sensitivity which is comparable to the parent line. It has also been shown that 
when indomethacin is applied to the parental cell line no toxic event was observed. The 
wild type cell line behaved the same in both the presence and absence o f indomethacin, 
while the resistant cell line was sensitivity was regained (Figure 29). Supporting studies 
used a MCF-7 cell line that is resistant to low doses o f doxorubicin. They indicated that a 
selective inhibitor for COX-2 called NS-398 restores the resistant lines sensitivity by 
increasing the intracellular doxorubicin accumulation in the cell, thereby inhibiting P-gp 
expression (30).
5.2 Conclusions and Recommendations for Further Study 
Several problems were encountered during the course o f this study. The development 
o f a resistant cell line can take from four months up to one year. Also, the first line 
developed was the MCF-7 cell line which was resistant to cisplatin. However, due to a 
change in FBS serum, the cell line ceased to proliferate, which resulted in the inability to 
fully characterize this cell line. Therefore, there is only a small amount o f data which 
supports drug resistance with this cell line. Ultimately, the MCF-7 resistant lines could 
not be studied due to the loss o f all o f  these lines. M DA-M B-231 resistant lines were 
developed late in the research progress, which limited the amount o f secondary testing
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that could be performed. Testing to determine resistance took longer than anticpated and 
microarray results took six weeks to analyze which further limited the amount o f time for 
additional study.
Microarray analysis show over expressed RNA species, but when we tried to validate 
this data by experiments which probed for protein product, a corelation was not observed. 
A possible explanation could be that the overexpressed mRNA from the microarray 
results may be degraded prior to translation due to a short poly A tail or alternative 
mechanisms such as ubiquitination which inhibit the mRNA being translated into protein. 
To confirm the microarray analysis semi quantitive RT-PCR was used. The PCR results 
demostrated similar results to the microarray data, indicated that mRNA o f the gene 
products are present. The bands seen for the amplification o f the gene products show the 
over expression observed in microarray studies (Figure 23-24). The resistant lines are 
producing increased levels o f mRNA for these proteins when compared to wild type. To 
determine if  gene expression was changing over time, we isolated fresh RNA and ran SQ- 
PCR and obtained similar results (Figure 25). These results ultimately lead to questioning 
the validity o f RNA microarray and supporting the use o f protein array analyses to 
determine biomarkers for resistance. Future studies in our lab include protein arrays on 
resistant lines and comparing that to both wild type protein array and the microarray data. 
Other research groups conclude that protein arrays would be the superior approach since 
they more closely resemble biochemical activity and given that protein concentrations do 
not correlate to mRNA levels (23,33).
Further testing o f the MMP-3 mechanism and using inhibitors for this protein would 
distinguish its mode o f action. TIMP (tissue inhibitor o f metalloproteinase) is an
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inhibitor o f MMPs. There are different TIMPs for the different 25 MMPs that are 
currently known (27). Inhibiting the action o f MMP-3 would allow us to determine if  this 
protein is another contributing factor to resistance that is observed with doxorubicin.
Determining the mechanism by which both o f these proteins are contributing to 
resistance is essential. Finding precursors to COX-2 and MMP-3 and determining if these 
proteins are involved in the same mechanism is crucial for determining factors of 
induciblity o f these proteins. An initial target o f this study should be IL-ip. Silencing this 
cytokine and then measuring the levels o f MMP-3 and COX-2 products downstream will 
confirm if  IL -ip  induces these proteins (27).
In conclusion, it appears that drug resistance in cancer cell lines can be reversed and 
drug sensitivity restored. Selective inhibitors o f COX-2 and other specific genes (known 
for resistance) are in need to prevent further damage to surrounding cells and limiting 
side effects such as cardiovascular problems. Also, it appears that microarray analysis 
does not corelate with protein data. Protein expressions o f over expressed genes were not 
observed, however end products o f the pathways were increased as demonstrated with 
COX-2 and PGE2 . Therefore, protein arrays should be used for future studies. Finding a 
mechanism by which COX-2 becomes induced in cancer cells and how PGE2 contributes 
to drug resistance and its overall affects on the cell should be further studied by 
determining how it there pathways induce tumor survival.
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